This inventor holds 2 USPTO granted patents. Top assignee: Hangzhou Adcoris Biopharma Co., Ltd.. Active years: 2023-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023-2025
Title: Zhenwei Miao: Innovator in Antibody-Drug Conjugates
Introduction
Zhenwei Miao is a prominent inventor based in Zhejiang, China. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of antibody-drug conjugates. With a total of 2 patents, Miao's work focuses on innovative solutions for cancer treatment.
Latest Patents
Miao's latest patents include the "Anti-HER2 antibody-drug conjugate and application thereof." This invention involves an anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate, which is designed for preparing an antitumor pharmaceutical product. Another notable patent is the "Anti-5T4 antibody-drug conjugate and use thereof." This invention provides an anti-5T4 antibody-drug conjugate and outlines its pharmaceutical use in inhibiting or preventing tumors.
Career Highlights
Zhenwei Miao is currently associated with Hangzhou Adcoris Biopharma Co., Ltd., where he continues to advance his research and development efforts. His work has been instrumental in the creation of novel therapeutic agents that target specific cancer markers.
Collaborations
Miao collaborates with esteemed colleagues such as Tong Zhu and Zhaohui Li, contributing to a dynamic research environment that fosters innovation in biopharmaceuticals.
Conclusion
Zhenwei Miao's contributions to the field of antibody-drug conjugates highlight his role as a key innovator in cancer treatment. His patents reflect a commitment to advancing medical science and improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile